Mayo Clinic Education will present a webinar on Wednesday, Oct. 29, 2025, that will describe the revolutionary way SAAmplify™–αSYN testing, which is offered by Mayo Clinic Laboratories in collaboration with Amprion, is improving diagnostic accuracy for patients with neurodegenerative disorders.

SAAmplify–αSYN is the first clinically available validated test that detects pathological α-synuclein with autopsy-confirmed accuracy — bringing unprecedented biological clarity to the diagnosis of diseases like Parkinson’s disease (PD), Lewy body dementia, and Alzheimer’s.

SAAmplify–αSYN, a seed amplification assay for the detection of misfolded α-synuclein in cerebrospinal fluid (CSF), is intended for patients with clinically uncertain cognitive decline or Parkinsonian syndromes. Results can help diagnose synucleinopathies, such as PD, dementia with Lewy bodies (DLB), Alzheimer's disease with Lewy body pathology (AD-LB), and multiple system atrophy (MSA). It is currently the only seed amplification assay commercially available to detect synucleinopathies in CSF and can accurately identify α-syn pathology before definitive symptoms appear.

Prior to the development of this assay, physicians were forced to diagnose based on clinical symptoms, missing the complex reality of mixed pathologies that define most neurodegenerative disorders.